Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin CohortCapsule Summary

• Main Authors: Yuki M.F. Andersen, MD, PhD (Author), Johan Sieborg, MSc (Author), Lea Nymand, MSc (Author), Tiago Torres, MD, PhD (Author), Andrea Chiricozzi, MD (Author), Simon Francis Thomsen, MD, PhD, DMSc (Author), Jacob P. Thyssen, MD, PhD, DMSc (Author), Alexander Egeberg, MD, PhD, DMSc (Author)
• Format: Book
• Published: Elsevier, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Oral Janus kinase inhibitors (JAKis) have black-box warnings of infections, cancer risk, and cardiovascular and venous thromboembolic events. They may be used off-label for chronic hand eczema (CHE). Objectives: Assess the prevalence of risk factors potentially impacting oral JAKi safety...